KLK3 and neoplasm: In terms of tumor responsiveness, PSA levels decreased by at least 30% in 4 of the 13 patients; one patient had a >98% decrease in PSA levels accompanied by significant proliferation of CAR-T cells in vivo, and 38.5% of patients maintained stable disease status at three months posttreatment assessed by imaging.